Migraine Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women who have not yet reached menopause and are 18 years of age or older
- Women who have a regular menstrual cycle that is between 21 and 32 days long
- People who have been diagnosed with chronic or episodic migraine
- Women who have been experiencing migraine with or without aura (a type of migraine with sensory warning signs) for at least one year, as classified by international headache guidelines
- Women who have had at least 2 days of migraine linked to their menstrual period, on average, in each of the last three periods
- Women who have already been keeping a daily headache diary as part of their regular care, with at least 3 months of recorded data before the study starts — the diary must include details such as headache days, pain severity, medications taken, menstrual bleeding days, and related symptoms
- Women who are willing to continue keeping their headache diary throughout the study
- Women for whom a treating doctor has decided to start fremanezumab (an anti-CGRP medication) as part of their usual care — this requires having had at least 8 migraine days per month over the last three months, meeting the criteria set in Switzerland for this type of treatment
- People who have signed the informed consent form agreeing to take part
Who may not be able to join:
- Women who only ever get migraines specifically during their menstrual period and at no other time (known as pure menstrual migraine)
- People who are already being treated with a different anti-CGRP medication (not fremanezumab)
- People who are not being treated with fremanezumab in line with its approved prescribing guidelines
- People who have used any other anti-CGRP-based migraine prevention medication within the 6 months before joining the study
- People who are currently participating in another interventional clinical trial for migraine
- People who change their hormone therapy during the study period
- People using progestin-only contraception (a type of hormonal birth control that contains only progestin)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christoph J Schankin, Prof, Inselspital, Department of Neurology, Bern
Phone: 00416322111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change of migraine days per month
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.